Pneumonia News and Research

Latest Pneumonia News and Research

CIHR and CMAJ honour eight Canadian Health Researchers

The Canadian Institutes of Health Research (CIHR) and the Canadian Medical Association Journal (CMAJ) today honoured eight outstanding Canadian individuals and teams with the first ever CIHR-CMAJ Top Canadian Achievements in Health Research Awards, which recognize and celebrate Canadian health research and innovation excellence.

29 Sep 2009

WHO lowers expectation of H1N1 vaccine output, appeals for donations to fight pandemic

International drug makers are expected to produce three billion doses of the H1N1 (swine flu) vaccine, "enough for just under half the world's population," a WHO official said Thursday, Canwest News Service/Ottawa Citizen reports. "The agency was hoping pharmaceutical companies would be able to make about five billion doses a year, but data collected over the summer led to the revised estimate," the news service writes (Fitzpatrick, 9/24).

25 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

NIST collaborates with private industry to release a new reference material for beryllium

Researchers at the National Institute of Standards and Technology (NIST), in collaboration with private industry and other government agencies, have produced a new reference material for beryllium. Beryllium, an exotic rare-earth metal used as a hardener in high-performance alloys and ceramics, can cause berylliosis-a chronic, incurable and sometimes fatal illness.

23 Sep 2009

British Prime Minister to unveil $1b effort to improve health systems in developing countries

During the U.N. General Assembly meeting in New York, British Prime Minister Gordon Brown on Wednesday is scheduled to announce that Britain is teaming up with Norway, the Netherlands and Australia to invest $1 billion to strengthen the health systems in developing countries, the Financial Times/NineMSN reports (Jack, 9/21).

23 Sep 2009

Also in Global Health news: HIV/aids in Zambia; Ugandan medical workers; Obama administration officials' Q&A, speech; South African health care reform efforts; texting to combat drug shortages in Africa

The Post of Zambia examines the findings of a recent report revealing "the devastating effects" the HIV/AIDS epidemic in Zambia is having on the country's ability to meet the U.N. Millennium Development Goals. The article also looks at the relationship between HIV/AIDS and nutrition, maternal health and education (Chackwe, 9/21).

21 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

SEQUENOM's first laboratory developed cystic fibrosis test launched

SEQUENOM, Inc. today announced that the company's first laboratory developed test, the SensiGene(TM) Cystic Fibrosis (CF) Carrier Screening test, has been launched.

18 Sep 2009

Plans could change how Medicare pays doctors, hospitals

Sen. Max Baucus' health proposal includes achieving cost savings, in part, by reconfiguring the way doctors and hospitals are paid for their services, The Wall Street Journal reports.

18 Sep 2009

Merck, Wellcome Trust to launch vaccine center in India to produce vaccines for developing countries

Pharmaceutical company Merck and the Wellcome Trust have joined together to create a non-profit, £90-million (about $150 million) research center in India to facilitate the development of new vaccines, "including [those for] neglected diseases for which inadequate or no vaccines exist," Nature News reports.

18 Sep 2009

MDVIP's medical director suggests preventive measures for flu

Dr. Bernard Kaminetsky, the medical director of MDVIP, a national network of affiliated primary care doctors focused on preventive care, recommends, “Talk to your primary care physician now about the flu, both seasonal and H1N1 flu. Your primary care doctor is the one who can best prepare you for the upcoming season with vaccinations as well as information specific to you.”

16 Sep 2009

Pros and cons of HIV treatments in developing countries

Palumbo is co-leading a clinical study of anti-HIV medicines in Africa and India for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). The randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP).

16 Sep 2009

Risk for patients contracting pneumonia increases threefold when treated with pantoprazole: Study

A popular stomach-acid reducer used to prevent stress ulcers in critically ill patients needing breathing machine support increases the risk of those patients contracting pneumonia threefold, according to researchers at Wake Forest University School of Medicine.

15 Sep 2009

Study reveals that daily bathroom showers may deliver pathogenic bacteria

While daily bathroom showers provide invigorating relief and a good cleansing for millions of Americans, they also can deliver a face full of potentially pathogenic bacteria, according to a surprising new University of Colorado at Boulder study.

15 Sep 2009

Boston University launches $10M, 5-year Global Health Center

Boston University (BU) on Monday launched a five-year, $10 million global health initiative that aims to "bolster research and education" and "build a nationwide consortium of universities devoted to improving health in the Third World," the Boston Globe reports.

14 Sep 2009

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.

14 Sep 2009

Final results of SAPHRIS clinical study released

Schering-Plough Corporation today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study.

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Clinical data emphasizing on efficacy and potency of torezolid to be presented

Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA.

14 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

Pneumonia News and Research

Latest Pneumonia News and Research

CIHR and CMAJ honour eight Canadian Health Researchers

WHO lowers expectation of H1N1 vaccine output, appeals for donations to fight pandemic

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

NIST collaborates with private industry to release a new reference material for beryllium

British Prime Minister to unveil $1b effort to improve health systems in developing countries

Also in Global Health news: HIV/aids in Zambia; Ugandan medical workers; Obama administration officials' Q&A, speech; South African health care reform efforts; texting to combat drug shortages in Africa

Millennium's sNDA for VELCADE granted priority review by the FDA

SEQUENOM's first laboratory developed cystic fibrosis test launched

Plans could change how Medicare pays doctors, hospitals

Merck, Wellcome Trust to launch vaccine center in India to produce vaccines for developing countries

MDVIP's medical director suggests preventive measures for flu

Pros and cons of HIV treatments in developing countries

Risk for patients contracting pneumonia increases threefold when treated with pantoprazole: Study

Study reveals that daily bathroom showers may deliver pathogenic bacteria

Boston University launches $10M, 5-year Global Health Center

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Final results of SAPHRIS clinical study released

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Clinical data emphasizing on efficacy and potency of torezolid to be presented

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Pneumonia News and Research

Latest Pneumonia News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in